Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment
Year: 2017
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Joseph G. Jurcic, Azra Raza, George Vlad, Eytan M. Stein, Mikhail Roshal, Dale Bixby, Daniel F. Boyer, Carlos E. Vigil, Sergei Syrbu, Mikkael A. Sekeres, Heesun J. Rogers, David A. Rizzieri, Anand S. Lagoo, Gail J. Roboz, Robert L. Redner, David P. Steensma, Rachel J. Cook, Tamara K. Moyo, Michael R. McKeown, Nigel J. Waters, K Stephens, Angela Volkert, Emmanuelle di Tomaso, David A. Roth, Jorge E. Cortés
Institutions: Columbia University Irving Medical Center, Columbia University, Memorial Sloan Kettering Cancer Center, University of Michigan, U-M Rogel Cancer Center, University of Iowa, Cleveland Clinic, Duke Medical Center, Weill Cornell Medicine, University of Pittsburgh, Dana-Farber Cancer Institute, Oregon Health & Science University, OHSU Knight Cancer Institute, Vanderbilt University, Syros Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2990467698